XML 107 R45.htm IDEA: XBRL DOCUMENT
v3.22.0.1

MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Kite Pharma, Inc. (Details) $ in Thousands | 1 Months Ended | 12 Months Ended |
--- | --- | --- | ---
Sep. 30, 2019 USD ($) | Apr. 30, 2018 USD ($) milestone | Dec. 31, 2021 USD ($) option | Dec. 31, 2020 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Accounts receivable |  |  | $ 6,013 | $ 5,224
Kite Pharma, Inc. | Collaboration and license agreement |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Milestone payments received |  | $ 150,000 |  |
Initial research term of agreement |  |  | 6 years |
Number of options to extend initial research term | option |  |  | 2 |
Extended research term of agreement |  |  | 1 year |
Separate fee for additional term |  |  | $ 10,000 |
Collaborative arrangement estimated reimbursable service costs for new research plan | $ 3,400 |  |  |
Collaborative arrangement transaction price | 189,300 |  |  |
Revenues under agreement | 150,000 |  |  |
Collaborative arrangement estimated reimbursable service costs | $ 39,300 |  |  |
Accounts receivable |  |  | 100 | 400
Deferred revenue |  |  | $ 56,500 | $ 81,400
Kite Pharma, Inc. | Collaboration and license agreement | Achievement of specified research, clinical development, regulatory and first commercial sale milestones |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Contingent development and sales-based milestone payments to be received |  | 1,300,000 |  |
Kite Pharma, Inc. | Collaboration and license agreement | Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Contingent development and sales-based milestone payments to be received |  | $ 1,800,000 |  |
Contingent Development And Sales Based Milestone Payments, Maximum Amount Of Achieved Milestones To Be Eligible For Payment | milestone |  | 10 |  |
Kite Pharma, Inc. | Collaboration and license agreement | Maximum |  |  |  |
Research and Development Arrangement, Contract to Perform for Others [Line Items] |  |  |  |
Development and sales-based milestone payments to be received |  | $ 3,000,000 |  |

X
- Definition Collaborative arrangement estimated reimbursable service costs. + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborative arrangement transaction price. + References No definition available. + Details
Name: | sgmo_CollaborativeArrangementTransactionPrice
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Contingent Development And Sales Based Milestone Payments, Maximum Amount Of Achieved Milestones To Be Eligible For Payment + References No definition available. + Details
Name: | sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsMaximumAmountOfAchievedMilestonesToBeEligibleForPayment
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contingent development and sales based milestone payments to be received. + References No definition available. + Details
Name: | sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Customer contract liability milestone payment eligible to receive. + References No definition available. + Details
Name: | sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Extended Research Term Of Agreement + References No definition available. + Details
Name: | sgmo_ExtendedResearchTermOfAgreement
Namespace Prefix: | sgmo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Initial research term of agreement. + References No definition available. + Details
Name: | sgmo_InitialResearchTermOfAgreement
Namespace Prefix: | sgmo_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone payments received. + References No definition available. + Details
Name: | sgmo_MilestonePaymentsReceived
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number Of Options To Extend Initial Research Term + References No definition available. + Details
Name: | sgmo_NumberOfOptionsToExtendInitialResearchTerm
Namespace Prefix: | sgmo_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Separate upfront fee. + References No definition available. + Details
Name: | sgmo_SeparateUpfrontFee
Namespace Prefix: | sgmo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 45 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |